Patents by Inventor HONGSHANG CHANG

HONGSHANG CHANG has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11484588
    Abstract: A paramyxovirus vaccine strain for novel coronavirus pneumonia and a construction method thereof are provided. The method includes performing a recombination of N and F genes of Newcastle disease virus type VII of Paramyxoviridae with P, M, H, L genes of Canine distemper virus of Paramyxoviridae to obtain a recombinant virus, inserting S1 gene of the novel coronavirus between the P and M genes of the recombinant virus to obtain a recombinant vector. The vaccine strain constructed can stably and efficiently express the novel coronavirus S1 protein, and induce the body to produce antibodies; and the recombined virus vaccine strain can stimulate the human body to produce mucosal immunity, and the prepared vaccine can be vaccinated through a nasal spray. Moreover, the vaccine strain can be tested in poultry and dogs, saving time, reducing costs, and being more conducive to actual production due to large output.
    Type: Grant
    Filed: August 17, 2021
    Date of Patent: November 1, 2022
    Assignee: QINGDAO HARWARS BIOLOGY GROUP LTD.
    Inventors: Mingyi Li, Gang Liu, Chunlin Yi, Fenglong Ma, Zongke Wang, Yujie Xia, Xiaochen Cui, Zhen Yang, Hongshang Chang, Bingbing Zhao, Jie Yang
  • Publication number: 20220323571
    Abstract: A paramyxovirus vaccine strain for novel coronavirus pneumonia and a construction method thereof are provided. The method includes performing a recombination of N and F genes of Newcastle disease virus type VII of Paramyxoviridae with P, M, H, L genes of Canine distemper virus of Paramyxoviridae to obtain a recombinant virus, inserting S1 gene of the novel coronavirus between the P and M genes of the recombinant virus to obtain a recombinant vector. The vaccine strain constructed can stably and efficiently express the novel coronavirus S1 protein, and induce the body to produce antibodies; and the recombined virus vaccine strain can stimulate the human body to produce mucosal immunity, and the prepared vaccine can be vaccinated through a nasal spray. Moreover, the vaccine strain can be tested in poultry and dogs, saving time, reducing costs, and being more conducive to actual production due to large output.
    Type: Application
    Filed: August 17, 2021
    Publication date: October 13, 2022
    Inventors: MINGYI LI, GANG LIU, CHUNLIN YI, FENGLONG MA, ZONGKE WANG, YUJIE XIA, XIAOCHEN CUI, ZHEN YANG, HONGSHANG CHANG, BINGBING ZHAO, JIE YANG